2007
DOI: 10.1001/archderm.143.2.223
|View full text |Cite
|
Sign up to set email alerts
|

Psoriasis and Pustular Dermatitis Triggered by TNF-α Inhibitors in Patients With Rheumatologic Conditions

Abstract: Background: New onset or worsening of psoriasis has been reported in patients treated with tumor necrosis factor ␣ (TNF-␣) inhibitors for a variety of rheumatologic conditions. There is mounting evidence that a key innate immune pathway for triggering common human autoimmune disease, including psoriasis, involves plasmacytoid dendritic cell precursors (PDCs) and type 1 interferon (IFN) production. We present herein a case series with clinical and histopathologic evidence of psoriasis in patients with rheumatol… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

10
265
3
18

Year Published

2007
2007
2017
2017

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 285 publications
(296 citation statements)
references
References 30 publications
(40 reference statements)
10
265
3
18
Order By: Relevance
“…32 TNF inhibits PDC maturation from hematopoietic progenitors as well as IFN-α production. 33 Subsequently, inhibition of TNF may allow unlimited and unregulated production of IFN-α by PDCs. Increased IFN-α expression was found in the dermal vasculature and in perivascular lymphocytic infiltrate of lesional skin of patients with TNF antagonist therapy.…”
Section: Discussionmentioning
confidence: 99%
“…32 TNF inhibits PDC maturation from hematopoietic progenitors as well as IFN-α production. 33 Subsequently, inhibition of TNF may allow unlimited and unregulated production of IFN-α by PDCs. Increased IFN-α expression was found in the dermal vasculature and in perivascular lymphocytic infiltrate of lesional skin of patients with TNF antagonist therapy.…”
Section: Discussionmentioning
confidence: 99%
“…The most common skin reaction associated with anti-TNF␣ treatment seems to be inflammatory skin conditions such as pustular psoriasis and eczema (45% of reactions) (5,6). New-onset psoriasis has been reported in patients treated with TNF␣ antagonists for a variety of rheumatologic conditions, with mounting evidence that the cross-reaction between TNF␣ and interferon may have a role in the pathogenesis of this reaction (6). We hypothesize that the case reported by Beuthien et al (1) could be pustular psoriasis of the palms and soles, triggered by TNF␣ inhibitor therapy.…”
Section: To the Editormentioning
confidence: 89%
“…Interferon (IFN)-α produced by dermal plasmacytoid dendritic cells has been identified as a key element in psoriatic skin lesion formation. As TNF-α regulates IFN-α production and the inhibition of TNF-α has been shown to induce the overexpression of IFN-α-regulated genes, therefore it is proposed that TNF-α inhibition might induce locally sustained IFN-α production in patients developing psoriasis while undergoing anti-TNF therapy [26] . In another research, anti-TNF drug-induced psoriasiform skin lesions are attributed to the infiltrates of interleukin (IL)-17A/ IL-22-expressing Th17 cells and IFN-expressing Th1 cells, and the severity of skin disease were positively correlated with the number of IL-17A-expressing T cells [27] .…”
Section: Discussionmentioning
confidence: 99%